Laquinimod (also known as Nerventra®)
Experimental Medications: Administered Orally
Company: Teva Neuroscience, Inc. and Active Biotech
- Oral medication taken once daily; dosing TBD (0.6 mg was used in studies)
- Being studied in RRMS and PPMS
The past year saw disappointing results from two trials – one in RRMS and the other in PPMS – for the immunomodulator laquinimod.
In May 2017, the medication’s developers announced that The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (CONCERTO) trial – evaluating 0.6 mg/daily capsule of laquinimod versus placebo – did not meet its primary endpoint of improvement in time to confirmed disability progression (CDP) after at least three months. While favorable results were seen in other endpoints, laquinimod did not achieve a statistically significant advantage over placebo in time to CDP over longer periods.40
Those disappointing results follow mixed findings from earlier studies. In the Phase III ALLEGRO study of 1,106 patients, for example, laquinimod reduced the annualized relapse rate by 23 percent and the progression of disability by 36 percent compared to placebo. However, in the BRAVO Phase III trial, which involved 1,300 participants, laquinimod failed to achieve its primary goal of reducing the annualized relapse rate. Based on the results of CONCERTO, Teva announced in May 2017 that “we have no current plans to further pursue laquinimod in RRMS.”40
In December 2017, Active Biotech, which is partnering with Teva in developing laquinimod, announced that the medication had not met the primary endpoint of a Phase II proof-of-concept study in PPMS.41 While these results make it unlikely that laquinimod will play a role in the treatment of MS, this medication continues to be studied for use in Huntington disease, a neurodegenerative disorder.